Kodiak Sciences Inc.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, with programs aimed at conditions such as geographic atrophy and glaucoma. It is also building a digital health platform, VETi, that combines proprietary LiDAR sensing, AI and wearable imaging concepts to support its retina franchise and related applications.

4.72

4.72

— Kodiak Sciences Inc.
%
Retinal disease drug candidates0% Investigational biologic therapies designed for retinal diseases such as geographic atrophy and glaucoma.
ABC platform programs0% Drug candidates built on Kodiak's Antibody Biopolymer Conjugate platform for longer-durability ocular treatment.
Digital health and wearable imaging0% VETi and related AI-enabled wearable headset and imaging technologies.
Research and development services100% Internal discovery, preclinical work, clinical development and regulatory preparation.

Kodiak does not currently sell commercial products and has not generated product revenue, so its direct customers are...

  • Retina specialists and ophthalmologistsprimary

    Would prescribe any approved retinal disease therapy for patients with GA, glaucoma or related indications.

  • Patients with retinal diseaseprimary

    End users of future therapies, especially patients needing durable intravitreal treatment options.

  • Clinical development partnerssecondary

    CROs, trial sites and manufacturers that enable development, testing and scale-up before approval.

  • Potential commercialization partnerssecondary

    Third parties that may help sell, market or distribute approved products if Kodiak outsources commercialization.

  • Digital health and research usersemerging

    Potential users of VETi or related prototype devices in imaging, identity security or cognitive science applications.

Kodiak is headquartered in the United States and its disclosed business activity is centered on U.S...

  • •Headquartered in the United States
  • •No product revenue disclosed because the company is pre-commercial
  • •Clinical development and regulatory activity are primarily U.S.-centric
  • •Future sales geography will depend on approval and partnering strategy
  • •Operational exposure is tied to trial sites, suppliers and collaborators

Kodiak’s strategy is to advance its ABC platform programs in geographic atrophy and glaucoma toward IND and eventual...

01
Advance ABC platform retinal programs toward INDshort-term

Clinical entry is the key value-creation step for a pre-commercial biotech.

02
Differentiate with durability and dual mechanism of actionmedium-term

Better efficacy and less frequent dosing could improve adoption versus current therapies.

03
Develop VETi and adjacent platform applicationsmedium-term

Broadens the technology base and may create optionality beyond the core retina franchise.

04
Secure funding and partnership flexibilityshort-term

The company needs capital and may need collaborators to reach commercialization.

Kodiak is a clinical-stage company with no approved products, so its value depends on successful development,...

critical

Clinical development failure or delay

The company is in clinical-stage development and its programs may not reach approval.

Scope
GA and glaucoma programs
Materiality
high
critical

Financing and going-concern risk

Kodiak has recurring losses, negative operating cash flow and limited cash runway.

Scope
Need to raise additional capital in 2026 and beyond
Materiality
high
high

Commercialization execution risk

The company has no sales or marketing infrastructure and may need third parties.

Scope
Future approved products
Materiality
high
high

Competitive pressure in retinal disease

Rivals may develop safer, more effective or more convenient therapies sooner.

Scope
Retinal disease indications
Materiality
high
medium

Cybersecurity and data protection

Remote work and sensitive IP increase exposure to phishing, ransomware and data loss.

Scope
Proprietary technology and confidential trial data
Materiality
medium
Research and development expense recognition
Affects quarterly operating loss and cash burn visibility
Stock-based compensation
Impacts operating expenses and adjusted profitability comparisons
Future collaboration or royalty arrangements
Could affect revenue timing, liabilities and cash flow presentation
Going-concern assessment
Signals financing dependence and affects risk assessment

Kodiak AI, Inc.

KDK · Services-Computer Integrated Systems Design

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

KIORA PHARMACEUTICALS INC

KPRX · Pharmaceutical Preparations

EASTMAN KODAK CO

KODK · Photographic Equipment & Supplies

MeiraGTx Holdings plc

MGTX · Biological Products, (No Diagnostic Substances)

Lineage Cell Therapeutics, Inc.

LCTX · Biological Products, (No Diagnostic Substances)

: 28/04/2026